Chongqing, China – From November 23 to November 25, Shanghai MicroPort Lifesciences Co., Ltd. ("MicroPort® Lifesciences") attended the 21th Scientific Meeting of the Chinese Diabetes Society (“CDS2017”) and displayed its La Fenice® Hypophyseal Hormone Infusion Pump and La Fenice® Insulin Pump in its booth. The CDS2017 was hosted by Chinese Medical Association and Chinese Diabetes Society and organized by Chongqing Medical Association.
Themed on “Collaborative Innovation and Integrated Development” and combined with the essences of ADA and EASD meeting in this year, the CDS2017 displayed the latest academic advancement and clinical application of the diabetes treatment industry. It also enlarged the extension of the diabetes and strengthened interdisciplinary cooperation. Experts of diabetes care and endocrinal management were invited to exchange ideas on clinical practice.
During the conference, many experts, including President of Chinese Endocrinologist Association Guang Ning of Shanghai Ruijin Hospital, visited MicroPort® Lifesciences booth to get a better understanding in its products. Academician Ning said, La Fenice® Hypophyseal Hormone Infusion Pump not only has good effect on the treatment of Idiopathic hypogonadotropic hypogonadism ("IHH") but also could help diagnose and treat idiopathic central secondary amenorrhea, and regulate menstrual cycles and boost the chance of pregnancy for patients with non-obesity polycystic ovarian syndrome ("PCOS").
Equipped with pulsatile infusion via micro pump technology, La Fenice® Hypophyseal Hormone Infusion Pump works as an artificial hypothalamus – it stimulates hypophysis to excrete follicle-stimulating hormone ("FSH") or luteinizing hormone ("LH") by simulating pulsatile excretion of GnRH in order to make patients recover from abnormally physiological adjustment function. It is the first domestically developed GnRH pulsatile pump. Since its market launch, a total of 134 babies were born with the help of La Fenice® Hypophyseal Hormone Infusion Pump.
Professor Jie Wen of Huashan Hospital of Fudan University offered previous suggestion on MicorPort® Lifesciences’ new generation 1.8T Insulin Pump. La Fenice® Insulin Pump works as an artificial pancreas. It can maintain stable blood glucose for the patient effectively and safely for throughout the day and night with its unique parameter index. La Fenice® Insulin Pump is specially designed for Chinese patients based on their eating habits and lifestyle. It is easy to operate and has precise dose. The device offers intensive treatment for diabetics in perioperative period to help them achieve faster postoperative recovery. La Fenice® Insulin Pump has been widely used in clinic and won recognition from industry experts since its market launch.
Since establishment, MicroPort® Lifesciences primarily focuses on the development and manufacturing of hypophyseal hormone infusion pump, insulin pump, and relevant disposables, to offer affordable and effective solution and service to patients suffering from diabetes and endocrinal diseases. In the future, MicroPort® Lifesciences will continue to devote itself to researching and developing more precise, more minimally invasive and smarter medical devices of diabetes and endocrine system, to benefit more patients and contribute to the healthcare industry.